

# GSK2033

Catalog No: tcsc0029828



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1221277-90-2

**Formula:**

$C_{29}H_{28}F_3NO_5S_2$

**Pathway:**

Metabolic Enzyme/Protease

**Target:**

LXR

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 30 mg/mL (50.70 mM; Need ultrasonic and warming)

**Observed Molecular Weight:**

591.66


## Product Description

GSK2033 is a **LXR** antagonist with **pIC<sub>50</sub>**s of 7 and 7.4 for **LXRα** or **LXRβ**, respectively.

IC<sub>50</sub> & Target: pIC<sub>50</sub>: 7 (LXRα), 7.4 (LXRβ)<sup>[1]</sup>

**In Vitro:** GSK2033 is a LXR antagonist with pIC<sub>50</sub>s of 7 and 7.4 for LXRα or LXRβ, respectively. GSK2033 dose-dependently suppresses basal transcription in full-length LXRα or full-length LXRβ cotransfection assays with IC<sub>50</sub>s of 17 nM and 9 nM, respectively. GSK2033 also effectively suppresses the transcription of an *ABCA1* driven luciferase reporter dose-dependently displaying IC<sub>50</sub>s of 52 nM for LXRα and 10 nM for LXRβ. GSK2033 also suppresses the expression of both of fatty acid synthase (*FASN*) and *SREBP1*<sup>[2]</sup>.

**In Vivo:** One month treatment of GSK2033 does not have significant effects on hepatic triglyceride levels. Plasma triglyceride levels are also unaffected by treatment with GSK2033<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!